<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02887118</url>
  </required_header>
  <id_info>
    <org_study_id>DREPADENSE</org_study_id>
    <nct_id>NCT02887118</nct_id>
  </id_info>
  <brief_title>Dense Red Blood Cells in Sickle Cell Children</brief_title>
  <acronym>DREPADENSE</acronym>
  <official_title>Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Quantitative and prognostic evaluation of dense red blood cells in sickle cell children:
      preliminary single center study from the Creteil pediatric cohort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An association between red blood cell density and hemolytic parameters, and clinical
      manifestations has been demonstrated in adults with sickle cell anemia.

      This factor has not been studied in children. The identification of predictive biomarkers of
      disease severity, especially of specific pediatric complications (cerebral vasculopathy,
      splenic sequestration, Dactylitis) would be useful for optimal care of the children and early
      intensification Red blood cell density might be one of these prognostic factors.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of dense red blood cells (DRBC)</measure>
    <time_frame>1 day</time_frame>
    <description>Evaluation of the number of dense red blood cells in the blood of affected children</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>biological profile</measure>
    <time_frame>1 day</time_frame>
    <description>hemolytic parameters (LDH, bilirubin, Hemoglobin level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with velocities &gt; 200 cm/sec on transcranial doppler</measure>
    <time_frame>1 day</time_frame>
    <description>Cerebral vasculopathy (correlation with patients with abnormal velocities on transcranial doppler (TCD)(&gt; 200 cm/sec)
History of dactylitis History of ischemic lesions on magnetic resonance imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with history of acute splenic sequestration,</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with history of acute chest syndrome</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with History of dactylitis</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with history of abnormal transcranial doppler (TCD) (≥ 200 cm/sec)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with history of ischemic lesions on magnetic resonance imaging (MRI)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hydroxycarbamide treatment</measure>
    <time_frame>1 day</time_frame>
    <description>effect of hydroxycarbamide on the % DRBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dense red blood cells</measure>
    <time_frame>1 day</time_frame>
    <description>number of dense red blood cells in the pediatric population with no known blood condition</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Common arm</arm_group_label>
    <description>Children with sickle cell anemia will be included. Blood samples of all the included patients will be collected during a day-hospitalization for a planned chek-up. For all these patients the number of dense erythrocytes will be evaluated</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples to study dense red blood cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with sickle cell disease followed regularly in the CHI creteil hospital aged from
        18 months to 18 years old.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 months-18 years

          -  Patient with sickle cell disease namely SS, or S / Beta0 or S / Beta +

          -  Patient regularly followed in the pediatric cohort of the CHI Creteil

          -  Patient Hospitalized for an annual check-up

          -  With or without intensification by Hydroxycarbamide

          -  patient who haven't been transfused within 3 months

          -  Whose parents have given their informed consent

          -  Patients insured to the French social scheme

        Exclusion Criteria:

          -  Sickle cell SC disease

          -  Having received an allogeneic bone marrow transplantation

          -  Under regular transfusion program

          -  Having received a transfusion within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Pondarre, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHI Créteil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHI Creteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000 Jan 13;342(2):83-9.</citation>
    <PMID>10631276</PMID>
  </reference>
  <reference>
    <citation>Benkerrou M, Alberti C, Couque N, Haouari Z, Ba A, Missud F, Boizeau P, Holvoet L, Ithier G, Elion J, Baruchel A, Ducrocq R. Impact of glucose-6-phosphate dehydrogenase deficiency on sickle cell anaemia expression in infancy and early childhood: a prospective study. Br J Haematol. 2013 Dec;163(5):646-54. doi: 10.1111/bjh.12590. Epub 2013 Oct 10.</citation>
    <PMID>24117340</PMID>
  </reference>
  <reference>
    <citation>Quinn CT, Shull EP, Ahmad N, Lee NJ, Rogers ZR, Buchanan GR. Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood. 2007 Jan 1;109(1):40-5. Epub 2006 Aug 29.</citation>
    <PMID>16940426</PMID>
  </reference>
  <reference>
    <citation>Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I, Coïc L, Leveillé E, Lemarchand E, Lesprit E, Abadie I, Medejel N, Madhi F, Lemerle S, Biscardi S, Bardakdjian J, Galactéros F, Torres M, Kuentz M, Ferry C, Socié G, Reinert P, Delacourt C. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011 Jan 27;117(4):1130-40; quiz 1436. doi: 10.1182/blood-2010-06-293514. Epub 2010 Nov 10.</citation>
    <PMID>21068435</PMID>
  </reference>
  <reference>
    <citation>Bartolucci P, Brugnara C, Teixeira-Pinto A, Pissard S, Moradkhani K, Jouault H, Galacteros F. Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis. Blood. 2012 Oct 11;120(15):3136-41. doi: 10.1182/blood-2012-04-424184. Epub 2012 Aug 23. Erratum in: Blood. 2014 Mar 20;123(12):1972.</citation>
    <PMID>22919030</PMID>
  </reference>
  <reference>
    <citation>Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012 Nov 22;120(22):4304-10; quiz 4448. doi: 10.1182/blood-2012-03-419879. Epub 2012 Aug 22. Erratum in: Blood. 2016 Dec 15;128(24):2869.</citation>
    <PMID>22915643</PMID>
  </reference>
  <reference>
    <citation>Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014 Sep 10;312(10):1033-48. doi: 10.1001/jama.2014.10517. Review. Erratum in: JAMA. 2014 Nov 12;312(18):1932. JAMA. 2015 Feb 17;313(7):729.</citation>
    <PMID>25203083</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Intercommunal Creteil</investigator_affiliation>
    <investigator_full_name>Corinne Pondarré</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Erythrocytes</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

